Get the latest news, insights, and market updates on ACHV (Achieve Life Sciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companiesSEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal Oct 20, 2025 - $ACHV
Achieve Life Sciences (ACHV) Is Up 36.4% After FDA Expedites Review of Vaping Cessation Therapy - What's Changed
Achieve Life Sciences announced that the U.S. Food and Drug Administration has awarded its investigational cytisinicline therapy a Commissioner's National Priority Voucher, enabling expedited review for its application as a treatment for nicotine dependence related to e-cigarette or vaping cessation. This rare designation, part of a new FDA program granted to only nine therapies in its first year, highlights an accelerating regulatory focus on solutions for the unmet medical need of vaping... Oct 19, 2025 - $ACHV
A Look at Achieve Life Sciences's Valuation After FDA Priority Voucher for Cytisinicline Therapy
Achieve Life Sciences (ACHV) has just received a rare Commissioner's National Priority Voucher from the FDA for its cytisinicline therapy targeting nicotine dependence in e-vaping. This move could sharply accelerate the drug's review process. See our latest analysis for Achieve Life Sciences. Following the FDA’s unique fast-track recognition, Achieve Life Sciences has seen its share price surge 41.9% over the past month and climb 56.7% in the past quarter. Regulatory momentum for... Oct 18, 2025 - $ACHV
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation
Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National Priority Voucher Program SEATTLE and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, tod Oct 17, 2025 - $ACHV
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that effective October 1, 2025, Achieve’s board of directors approved stock option grants to purchase an aggregate of 161,000 shares of its common stock for five new employees under Achi Oct 2, 2025 - $ACHV
ACHV: Preparations Continue as PDUFA Date Assigned
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced that its new drug application (NDA) for cytisinicline has been accepted by the FDA in a September 3 rd press release. Other important developments include the appointment of two internal employees to interim Chief Medical Officer (CMO) and Chief Operations Officer (COO). Sep 22, 2025 - $ACHV
Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer
Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operationsSEATTLE and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the promotion of Craig Donnelly to Chief Operations Officer. Mr. Donnelly has been with Sep 18, 2025 - $ACHV
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple